作者
Dipak Kotecha, Karina V Bunting, Simrat K Gill, Samir Mehta, Mary Stanbury, Jacqueline C Jones, Sandra Haynes, Melanie J Calvert, Jonathan J Deeks, Richard P Steeds, Victoria Y Strauss, Kazem Rahimi, A John Camm, Michael Griffith, Gregory YH Lip, Jonathan N Townend, Paulus Kirchhof
发表日期
2020/12/22
期刊
Jama
卷号
324
期号
24
页码范围
2497-2508
出版商
American Medical Association
简介
Importance
There is little evidence to support selection of heart rate control therapy in patients with permanent atrial fibrillation, in particular those with coexisting heart failure.
Objective
To compare low-dose digoxin with bisoprolol (a β-blocker).
Design, Setting, and Participants
Randomized, open-label, blinded end-point clinical trial including 160 patients aged 60 years or older with permanent atrial fibrillation (defined as no plan to restore sinus rhythm) and dyspnea classified as New York Heart Association class II or higher. Patients were recruited from 3 hospitals and primary care practices in England from 2016 through 2018; last follow-up occurred in October 2019.
Interventions
Digoxin (n = 80; dose range, 62.5-250 μg/d; mean dose, 161 μg/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; mean dose, 3.2 mg/d).
Main Outcomes and Measures
The primary end point was patient-reported quality of life using the …
学术搜索中的文章
D Kotecha, KV Bunting, SK Gill, S Mehta, M Stanbury… - Jama, 2020